CTRI/2012/04/002601已完成2 期
A Phase II randomized, double blind placebo controlled study to evaluate the efficacy and safety of Under Eye Cream in healthy human volunteers
Sami labs0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and female subjects in generally good health.
- •Subjects of skin types III, IV, and V.
- •Subjects age group 18 - 55 years
- •Subjects willing to give a written informed consent and come for a regular follow up.
- •Subject willing to abide by and comply with the study protocol.
- •Subject has not participated in a similar investigation in the past four weeks.
- •Subjects having mild to severe infra orbital melanosis and fine lines.
- •Subjects with no history of glaucoma, any eye infection.
- •Subjects who have not taken any under eye treatments for at least 14 days prior to
- •Subject should be willing to abstain from spa treatments/facials during the study period.
- •Subject is not pregnant (as determined by interview),and she must agree to use an active
- •form of birth control (i.e, stabilized on oral contraceptives, condom and /or spermicidal foam,
- •IUD, implant, or diaphragm ) for the duration of the study.
排除标准
- •Pregnant or nursing female (as determined by interview).
- •A known history or present condition of allergic response to any cosmetic products.
- •Concomitant topical therapy in under eye area that causes hypopigmentation includes Retinoids and Hydroquinone skin peels.
- •Subjects taking concomitant therapy (such as oral anti oxidants, vitamin E) that might interfere with the study results.
- •Subjects with dermatological disorder of face that may interfere with study evaluation.
- •Subjects with history of abnormal intraocular pressure, history of glaucoma and any eye
- •infection during enrolment
- •Concomitant medicines, that cause hyper pigmentation, include Phenothiazines, Anti-malarials (Chloroquine), Phenytoin sodium, cytotoxic drugs, Sulphonamides.
- •Systemic treatment which may modify the cutaneous state on the day of inclusion or in the previous 30 days, including retinoid therapy.
- •Subjects not willing to discontinue other topical anti ageing, anti wrinkle facial products.
- •Hypersensitivity to any component of the tested products.
- •History of intense sun exposure.
- •Chronic illness which may influence the cutaneous state.
- •Subject participating in any other cosmetic or therapeutic trial.
- •Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness.
- •Subjects who have undergone filler treatment under the eye within the past three months.
研究者
相似试验
进行中(未招募)
1 期
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.neoadjuvant hormone-receptor positive HER2-negative breast cancerMedDRA version: 16.0Level: LLTClassification code 10006204Term: Breast carcinomaSystem Organ Class: 100000004864EUCTR2013-001862-41-ITovartis Farma S.p.A372
进行中(未招募)
1 期
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.neoadjuvant hormone-receptor positive HER2-negative breast cancerEUCTR2013-001862-41-CZovartis Pharma Services AG372
进行中(未招募)
1 期
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.EUCTR2013-001862-41-BEovartis Pharma Services AG372
进行中(未招募)
1 期
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.neoadjuvant hormone-receptor positive HER2-negative breast cancerEUCTR2013-001862-41-DEovartis Pharma Services AG372
进行中(未招募)
1 期
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.neoadjuvant hormone-receptor positive HER2-negative breast cancerEUCTR2013-001862-41-NLovartis Pharma Services AG372
